Over the past decade, major advancements in the understanding of
the molecular mechanisms and pathophysiology of pulmonary
hypertension occurred in parallel with the discovery and
development of new therapies. Pharmacological agents that modulate
the main pathophysiological pathways of pulmonary arterial
hypertension have changed the course of this devastating disease by
relieving symptoms and improving and prolonging patients lives.
The first part of the book covers definition, classification,
pathophysiology, pathology, biomarkers and animal models of
pulmonary hypertension, thus laying the conceptual basis for what
follows. The middle section provides an overview of the established
therapies, such as calcium channel blockers, prostanoids,
endothelin receptor antagonists, phosphodiesterase-5 inhibitors and
inhaled nitric oxide. The concluding section explores novel
pathways and emerging therapeutic approaches including soluble
guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of
serotonin receptors and transporters, peptide growth factors,
vasoactive peptides, modulators of redox equilibrium and cyclic
nucleotides homeostasis, as well as immunosuppressive and
anti-proliferative agents. Particular attention is given to
clinical applications of these experimental therapies. "
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!